Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.25USD
23 May 2018
Change (% chg)

$0.01 (+3.58%)
Prev Close
$0.25
Open
$0.26
Day's High
$0.26
Day's Low
$0.24
Volume
30,137
Avg. Vol
150,687
52-wk High
$0.82
52-wk Low
$0.21

Chart for

About

ContraVir Pharmaceuticals, Inc. is focused on curing hepatitis B through the combination of direct and indirect acting antiviral compounds. Its two assets tenofovir exalidex, or TXL, and CRV431 have complementary mechanisms of action and have shown potential synergy against hepatitis B virus (HBV). TXL is designed to deliver... (more)

Overall

Beta: 1.54
Market Cap(Mil.): $48.36
Shares Outstanding(Mil.): 78.00
Dividend: --
Yield (%): --

Financials

  CTRV.OQ Industry Sector
P/E (TTM): -- 84.06 32.75
EPS (TTM): -0.29 -- --
ROI: -126.93 1.57 14.38
ROE: -- 2.43 16.07

BRIEF-Contravir Pharma Files For Series C Convertible Preferred Stock

* CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2wUNyv5) Further company coverage:

May 18 2018

BRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock

* CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING Source text : [http://bit.ly/2p2XwU7] Further company coverage:

Mar 09 2018

BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population

* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

Feb 12 2018

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

Feb 06 2018

BRIEF-Contravir Pharmaceuticals adjourns annual meeting of stockholders until Dec 21

* CONTRAVIR PHARMACEUTICALS ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF STOCKHOLDERS UNTIL DECEMBER 21, 2017

Dec 13 2017

Earnings vs. Estimates